Bayer Looks To Turn Aleve Sales Around Following Negative Media Hit
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of OTC naproxen benefited from COX-2 safety concerns initially, but felt repercussions from the National Institutes of Health’s December decision to halt the ADAPT study due to issues surrounding the drug.
You may also be interested in...
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
USP Advisory Group To Evaluate International Harmonization Efforts
A committee comprising stakeholders will discuss ways of improving USP's work with international pharmacopeias to harmonize excipient monographs and general chapters.